Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07595276 Cetuximab biosimilar (Zhangjiang Biotech) Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07595276 clinical trial report covering Cetuximab biosimilar (Zhangjiang Biotech), Phase 3, endpoints, sponsor, geography, readout timing and development w
Latest Hotspot
8 min read
NCT07595549 Berobenatide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07595549 clinical trial report covering Berobenatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07596199 Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed(GlaxoSmi Diphtheria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07596199 clinical trial report covering Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed(GlaxoSmi, Phase 3, endpoints, sponsor, geog
Latest Hotspot
8 min read
NCT07596173 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbe Diphtheria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07596173 clinical trial report covering Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbe, Phase 3, endpoints, sponsor, geog
Latest Hotspot
8 min read
NCT07595913 Alveltamig Advanced Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07595913 clinical trial report covering Alveltamig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07596784 Ravulizumab-CWVZ Myasthenia Gravis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07596784 clinical trial report covering Ravulizumab-CWVZ, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261823 GBI268 Acute Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261823 clinical trial report covering GBI268, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261996 [18F]Florzolotau Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261996 clinical trial report covering [18F]Florzolotau, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600125057 Pucotenlimab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
ChiCTR2600125057 clinical trial report covering Pucotenlimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07598864 Finerenone Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07598864 clinical trial report covering Finerenone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262015 Human Coagulation Factor IX (Shandong Taibang) Hemorrhage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20262015 clinical trial report covering Human Coagulation Factor IX (Shandong Taibang), Phase 3, endpoints, sponsor, geography, readout timing and developm
Latest Hotspot
8 min read
NCT07604103 Trivalent Influenza virus split vaccine(Sanofi) Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07604103 clinical trial report covering Trivalent Influenza virus split vaccine(Sanofi), Phase 3, endpoints, sponsor, geography, readout timing and develop